Skip to main content
Top
Published in: Experimental & Translational Stroke Medicine 1/2011

Open Access 01-12-2011 | Research

Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model

Authors: R Christian Crumrine, Victor J Marder, G McLeod Taylor, Joseph C LaManna, Constantinos P Tsipis, Philip Scuderi, Stephen R Petteway Jr, Vikram Arora

Published in: Experimental & Translational Stroke Medicine | Issue 1/2011

Login to get access

Abstract

Background

Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is extended. However, because IA administration delivers a higher local concentration of agent, the incidence and severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously hypertensive rat (SHR).

Methods

Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured.

Results

Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV 10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA or IV route had greater neurological dysfunction compared to all other groups.

Conclusions

Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Cole-Haskayne A, Ryckborst K, Sopher L, Button A, Hu W, Hudon ME, Morrish W, Frayne R, Sevick RJ, Buchan AM: Acute intravenous-intra-arterial revascularization therapy for severe ischemic stroke. Stroke 2002, 33: 279–282. 10.1161/hs0102.101900PubMedCrossRef Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Cole-Haskayne A, Ryckborst K, Sopher L, Button A, Hu W, Hudon ME, Morrish W, Frayne R, Sevick RJ, Buchan AM: Acute intravenous-intra-arterial revascularization therapy for severe ischemic stroke. Stroke 2002, 33: 279–282. 10.1161/hs0102.101900PubMedCrossRef
2.
go back to reference Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama 1999, 282: 2003–2011. 10.1001/jama.282.21.2003PubMedCrossRef Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama 1999, 282: 2003–2011. 10.1001/jama.282.21.2003PubMedCrossRef
3.
go back to reference Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999, 30: 2598–2605. 10.1161/01.STR.30.12.2598PubMedCrossRef Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999, 30: 2598–2605. 10.1161/01.STR.30.12.2598PubMedCrossRef
4.
go back to reference Mathews MS, Sharma J, Snyder KV, Natarajan SK, Siddiqui AH, Hopkins LN, Levy EI: Safety, effectiveness, and practicality of endovascular therapy within the first 3 hours of acute ischemic stroke onset. Neurosurgery 2009, 65: 860–865. discussion 865 10.1227/01.NEU.0000358953.19069.E5PubMedCrossRef Mathews MS, Sharma J, Snyder KV, Natarajan SK, Siddiqui AH, Hopkins LN, Levy EI: Safety, effectiveness, and practicality of endovascular therapy within the first 3 hours of acute ischemic stroke onset. Neurosurgery 2009, 65: 860–865. discussion 865 10.1227/01.NEU.0000358953.19069.E5PubMedCrossRef
5.
go back to reference Sen S, Huang DY, Akhavan O, Wilson S, Verro P, Solander S: IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocrit Care 2009, 11: 76–81. 10.1007/s12028-009-9204-1PubMedCrossRef Sen S, Huang DY, Akhavan O, Wilson S, Verro P, Solander S: IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocrit Care 2009, 11: 76–81. 10.1007/s12028-009-9204-1PubMedCrossRef
6.
go back to reference Talecris, Biotherapeutics: A safety and dose finding study of plasmin (human) administered into the middle cerebral artery of stroke patients. U.S. National Institutes of Health, clinical trials website; 2009. [http://www.clinicaltrials.gov] Talecris, Biotherapeutics: A safety and dose finding study of plasmin (human) administered into the middle cerebral artery of stroke patients. U.S. National Institutes of Health, clinical trials website; 2009. [http://​www.​clinicaltrials.​gov]
7.
go back to reference Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T: Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2009, 27: 368–374. 10.1159/000202427PubMedCentralPubMedCrossRef Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T: Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2009, 27: 368–374. 10.1159/000202427PubMedCentralPubMedCrossRef
8.
go back to reference Furlan AJ: Acute stroke therapy: beyond i.v. tPA. Cleve Clin J Med 2002, 69: 730–734. 10.3949/ccjm.69.9.730PubMedCrossRef Furlan AJ: Acute stroke therapy: beyond i.v. tPA. Cleve Clin J Med 2002, 69: 730–734. 10.3949/ccjm.69.9.730PubMedCrossRef
9.
go back to reference NINDS Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333: 1581–1587.CrossRef NINDS Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333: 1581–1587.CrossRef
10.
go back to reference Lisboa RC, Jovanovic BD, Alberts MJ: Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke 2002, 33: 2866–2871. 10.1161/01.STR.0000038987.62325.14PubMedCrossRef Lisboa RC, Jovanovic BD, Alberts MJ: Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke 2002, 33: 2866–2871. 10.1161/01.STR.0000038987.62325.14PubMedCrossRef
11.
go back to reference Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359: 1317–1329. 10.1056/NEJMoa0804656PubMedCrossRef Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359: 1317–1329. 10.1056/NEJMoa0804656PubMedCrossRef
12.
go back to reference Molina CA: Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 2011, 42: S16–19. 10.1161/STROKEAHA.110.598763PubMedCrossRef Molina CA: Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 2011, 42: S16–19. 10.1161/STROKEAHA.110.598763PubMedCrossRef
13.
go back to reference Sandercock PAG: IST-3 Study Protocol: Third international stroke trial: thrombolysis for acute ischaemic stroke. IST-3 full trial protocol V1.93 2009. [http://www.ist3.com] Sandercock PAG: IST-3 Study Protocol: Third international stroke trial: thrombolysis for acute ischaemic stroke. IST-3 full trial protocol V1.93 2009. [http://​www.​ist3.​com]
14.
go back to reference Welsh FA, Sakamoto T, McKee AE, Sims RE: Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain. J Neurochem 1987, 49: 846–851. 10.1111/j.1471-4159.1987.tb00971.xPubMedCrossRef Welsh FA, Sakamoto T, McKee AE, Sims RE: Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain. J Neurochem 1987, 49: 846–851. 10.1111/j.1471-4159.1987.tb00971.xPubMedCrossRef
15.
go back to reference Seta KA, Crumrine RC, Whittingham TS, Lust WD, McCandless WD: Experimental models of human stroke. In Neuromethods, Volume 22: Animal models of neurological disease, II; metabolic encephalopathies and the epilepsies. Edited by: Boulton AA, Baker GB, Butterworth RF. Totowana, NJ: The Humana Press; 1992:1–50.CrossRef Seta KA, Crumrine RC, Whittingham TS, Lust WD, McCandless WD: Experimental models of human stroke. In Neuromethods, Volume 22: Animal models of neurological disease, II; metabolic encephalopathies and the epilepsies. Edited by: Boulton AA, Baker GB, Butterworth RF. Totowana, NJ: The Humana Press; 1992:1–50.CrossRef
16.
go back to reference Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ: A critical reevaluation of the intraluminal thread model of focal cerebral ischemia: evidence of inadvertent premature reperfusion and subarachnoid hemorrhage in rats by laser-Doppler flowmetry. Stroke 1998, 29: 2162–2170. 10.1161/01.STR.29.10.2162PubMedCrossRef Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ: A critical reevaluation of the intraluminal thread model of focal cerebral ischemia: evidence of inadvertent premature reperfusion and subarachnoid hemorrhage in rats by laser-Doppler flowmetry. Stroke 1998, 29: 2162–2170. 10.1161/01.STR.29.10.2162PubMedCrossRef
17.
go back to reference Zhao Q, Memezawa H, Smith ML, Siesjo BK: Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament. Brain Res 1994, 649: 253–259. 10.1016/0006-8993(94)91071-5PubMedCrossRef Zhao Q, Memezawa H, Smith ML, Siesjo BK: Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament. Brain Res 1994, 649: 253–259. 10.1016/0006-8993(94)91071-5PubMedCrossRef
18.
go back to reference Shaw GJ, Sperling M, Meunier JM: Long-term stability of recombinant tissue plasminogen activator at -80 C. BMC Res Notes 2009, 2: 117. 10.1186/1756-0500-2-117PubMedCentralPubMedCrossRef Shaw GJ, Sperling M, Meunier JM: Long-term stability of recombinant tissue plasminogen activator at -80 C. BMC Res Notes 2009, 2: 117. 10.1186/1756-0500-2-117PubMedCentralPubMedCrossRef
19.
go back to reference Korninger C, Collen D: Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981, 46: 561–565.PubMed Korninger C, Collen D: Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981, 46: 561–565.PubMed
20.
go back to reference Wang CX, Ding X, Shuaib A: Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. Exp Neurol 2008, 213: 171–175. 10.1016/j.expneurol.2008.05.020PubMedCrossRef Wang CX, Ding X, Shuaib A: Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. Exp Neurol 2008, 213: 171–175. 10.1016/j.expneurol.2008.05.020PubMedCrossRef
21.
go back to reference Haelewyn B, Risso JJ, Abraini JH: Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats? J Cereb Blood Flow Metab 2010, 30: 900–903. 10.1038/jcbfm.2010.33PubMedCentralPubMedCrossRef Haelewyn B, Risso JJ, Abraini JH: Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats? J Cereb Blood Flow Metab 2010, 30: 900–903. 10.1038/jcbfm.2010.33PubMedCentralPubMedCrossRef
22.
go back to reference Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM: Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17: 1304–1308. 10.1161/01.STR.17.6.1304PubMedCrossRef Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM: Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17: 1304–1308. 10.1161/01.STR.17.6.1304PubMedCrossRef
23.
go back to reference Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17: 472–476. 10.1161/01.STR.17.3.472PubMedCrossRef Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17: 472–476. 10.1161/01.STR.17.3.472PubMedCrossRef
24.
go back to reference Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W: Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 1988, 8: 474–485. 10.1038/jcbfm.1988.88PubMedCrossRef Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W: Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 1988, 8: 474–485. 10.1038/jcbfm.1988.88PubMedCrossRef
25.
go back to reference Aronowski J, Strong R, Grotta JC: Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 1997, 17: 1048–1056.PubMedCrossRef Aronowski J, Strong R, Grotta JC: Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 1997, 17: 1048–1056.PubMedCrossRef
26.
go back to reference Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC: Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 2000, 31: 1812–1816. 10.1161/01.STR.31.8.1812PubMedCrossRef Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC: Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 2000, 31: 1812–1816. 10.1161/01.STR.31.8.1812PubMedCrossRef
28.
go back to reference Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363: 768–774.PubMedCrossRef Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363: 768–774.PubMedCrossRef
29.
go back to reference Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S: Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 2001, 101: 493–500. 10.1016/S0049-3848(00)00414-XPubMedCrossRef Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S: Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 2001, 101: 493–500. 10.1016/S0049-3848(00)00414-XPubMedCrossRef
30.
go back to reference del Zoppo GJ, von Kummer R, Hamann GF: Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998, 65: 1–9. 10.1136/jnnp.65.1.1PubMedCentralPubMedCrossRef del Zoppo GJ, von Kummer R, Hamann GF: Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998, 65: 1–9. 10.1136/jnnp.65.1.1PubMedCentralPubMedCrossRef
31.
go back to reference Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM: The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004, 24: 945–963.PubMedCrossRef Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM: The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004, 24: 945–963.PubMedCrossRef
32.
go back to reference Overgaard K, Sereghy T, Pedersen H, Boysen G: Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport 1992, 3: 925–928. 10.1097/00001756-199210000-00027PubMedCrossRef Overgaard K, Sereghy T, Pedersen H, Boysen G: Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport 1992, 3: 925–928. 10.1097/00001756-199210000-00027PubMedCrossRef
33.
go back to reference Burggraf D, Martens HK, Dichgans M, Hamann GF: rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia. Brain Res 2007, 1164: 55–62.PubMedCrossRef Burggraf D, Martens HK, Dichgans M, Hamann GF: rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia. Brain Res 2007, 1164: 55–62.PubMedCrossRef
34.
go back to reference Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R: Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003, 34: 2975–2979. 10.1161/01.STR.0000101914.62066.7BPubMedCrossRef Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R: Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003, 34: 2975–2979. 10.1161/01.STR.0000101914.62066.7BPubMedCrossRef
35.
go back to reference Kahles T, Foerch C, Sitzer M, Schroeter M, Steinmetz H, Rami A, Neumann-Haefelin T: Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent. Vascul Pharmacol 2005, 43: 254–259. 10.1016/j.vph.2005.07.008PubMedCrossRef Kahles T, Foerch C, Sitzer M, Schroeter M, Steinmetz H, Rami A, Neumann-Haefelin T: Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent. Vascul Pharmacol 2005, 43: 254–259. 10.1016/j.vph.2005.07.008PubMedCrossRef
Metadata
Title
Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
Authors
R Christian Crumrine
Victor J Marder
G McLeod Taylor
Joseph C LaManna
Constantinos P Tsipis
Philip Scuderi
Stephen R Petteway Jr
Vikram Arora
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Experimental & Translational Stroke Medicine / Issue 1/2011
Electronic ISSN: 2040-7378
DOI
https://doi.org/10.1186/2040-7378-3-10

Other articles of this Issue 1/2011

Experimental & Translational Stroke Medicine 1/2011 Go to the issue